Oklahoma Senate Bill SB1658

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Health care; creating the Informed Consent and Medical Transparency Act; imposing certain duties on drug manufacturers, hospitals, and health care providers. Effective date.

Summary

SB1658 creates the “Informed Consent and Medical Transparency Act” and is aimed at expanding disclosure around drugs, vaccines, and biologics used in Oklahoma. The bill requires manufacturers to prepare plain-language summaries of known or reasonably suspected side effects and adverse events that are material to informed consent, including rare but serious or life-threatening risks, and to update those summaries when new credible safety information becomes available. Manufacturers must send the current summaries to the State Board of Pharmacy for public posting and to hospitals, pharmacies, and licensed prescribers. The bill also places duties on hospitals, health care facilities, and licensed providers to give the manufacturer’s current summary to patients or their legal guardians before administering or prescribing covered products. It requires suspected adverse events to be documented in existing medical record systems and reported to the State Board of Pharmacy within 10 business days. The measure creates civil liability for negligent noncompliance, allows injured patients to sue for damages and attorney fees, and authorizes the Attorney General or a district attorney to pursue consumer-protection actions for patterns of noncompliance.

Impact

SB1658 would add a new state-law disclosure and reporting regime in Title 59, Section 355.5, imposing affirmative duties on drug manufacturers, hospitals, and health care providers that go beyond ordinary informed-consent practices. It would also create a new private right of action for patients, potential joint and several liability for retaliation against reporting employees, and enforcement authority under the Oklahoma Consumer Protection Act. The bill expressly states that it does not alter federal drug approval or labeling requirements and is intended to operate as an independent state transparency requirement.

Sentiment

There is no recorded committee debate or vote history in the provided materials, so the bill’s sentiment cannot be measured from floor or committee remarks. Based on the text alone, the measure appears to be framed as a patient-rights and transparency bill, with supporters likely emphasizing informed consent, public access to safety information, and accountability for nonreporting. The absence of opposition testimony or vote data means there is no documented legislative sentiment beyond the bill’s stated purpose.

Contention

The main points of potential contention are the scope of the disclosure obligations, the reporting burden on manufacturers and providers, and the bill’s liability provisions. Manufacturers may object to the requirement to generate and continually update plain-language safety summaries and distribute them broadly, while hospitals and providers may view the patient-delivery and adverse-event reporting mandates as administratively burdensome. Another likely flashpoint is the private right of action and the possibility of consumer-protection enforcement, which could expose covered entities to litigation over alleged noncompliance. The bill also anticipates preemption concerns by stating it does not conflict with federal law, suggesting that federal-state authority over drug labeling and safety could be a legal issue.